On may 11, 2017, was held the annual general meeting of LIDDS AB (publ). Below is a summary of the decisions taken. Decisions were passed with the requisite majority.
The meeting was attended by 355 461 (19,5%) of the total 18 225 990 shares represented.
At the meeting, it was decided to establish the presented income statement and balance sheet. At the meeting, it was decided also to dispose of the company’s profit according to the proposal of the board in the annual report. Furthermore, it was decided that no dividend be paid for fiscal year 2016.
The annual general meeting decided on the discharge for members of the board and chief executive officer.
The agm decided that the board of directors shall consist of five members and to appoint one auditor with no deputy auditor.
At the meeting it was decided that the board fee shall be paid by 120 000 sek to the chairman of the board and with sek 60,000 to each of the other board members. It was further decided that the auditor should be paid according to approved invoices.
The annual general meeting resolved to re-elect Jan Törnell, Anders Bjartell, Maria Forss and IngaLill Forslund Larsson as board members and to select the Daniel Lifveredson as a new board member. Jan Törnell was appointed chairman of the board of directors.
The meeting re-elected Mazars SET accounting Firm LTD, to the auditor, with Andreas Brodström and Martin Force as principal.
All of the options above relate to the period until the next annual meeting of shareholders.
The meeting approved the procedure for electing nomination committee for the agm in 2018 and adopted the instruction and charter for the nomination committee.
The board of directors decided to authorize the board of directors to, on one or several occasions during the period until the next agm, with or without deviation from shareholders ‘ preferential rights, resolve on new issue of shares. Issue may be able to be made with or without prescript-cash consideration, set-off or other conditions. The number of shares to be issued shall in total not exceed a number corresponding to twenty percent of the total number of shares in the company at the time of the annual general meeting and the issue price must be competitive. The purpose of the authorization is to be able to raise working capital with the goal to strengthen the structure, to be able to accelerate development projects and to allow the issue to industrial partners within the framework of collaborations and alliances.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com
The information in this press release is such that LIDDS is obliged to publish under the EU marknadsmissbruksförordning and the law on the securities market. The information was submitted, by the above contact person in the government, for publication on 11 may 2017 there is a 17:10 CET.
LIDDS development of effective pharmaceutical products against different kinds of cancer with the patented NanoZolid®technology. NanoZolid releases the drug locally and efficiently, in close proximity to the tumor, which means significantly less side effects compared with systemic treatment. NanoZolid®-technology provides the possibility of a controlled and tailored release of drug for up to six months. NanoZolid® can integrate both smaller and larger drug molecules.ex. anticancer drugs and antibodies. The company’s most advanced project, prostate-cancerprodukten Liproca® Depot containing 2-hydroxyflutamide, validates that the technology platform works. Industrial scale production is carried out in collaboration with Recipharm. LIDDS has active development projects in which NanoZolid be combined with anti-androgens, chemotherapy and immune-active substances. For more information, see www.lidds.se. Redeye AB is LIDDS certified adviser.
The news in PDF
